Yvette Bernal

7.9k total citations
22 papers, 459 citations indexed

About

Yvette Bernal is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Yvette Bernal has authored 22 papers receiving a total of 459 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 8 papers in Public Health, Environmental and Occupational Health and 6 papers in Immunology. Recurrent topics in Yvette Bernal's work include CAR-T cell therapy research (19 papers), Acute Lymphoblastic Leukemia research (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). Yvette Bernal is often cited by papers focused on CAR-T cell therapy research (19 papers), Acute Lymphoblastic Leukemia research (8 papers) and Biosimilars and Bioanalytical Methods (6 papers). Yvette Bernal collaborates with scholars based in United States, Switzerland and Poland. Yvette Bernal's co-authors include Renier J. Brentjens, Jae H. Park, Michel Sadelain, Xiuyan Wang, Isabelle Rivière, Elizabeth Halton, Terence J. Purdon, Kevin J. Curran, Craig S. Sauter and Brigitte Sénéchal and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular Therapy.

In The Last Decade

Yvette Bernal

21 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yvette Bernal United States 11 375 142 135 117 73 22 459
Chunrong Tong China 11 337 0.9× 108 0.8× 113 0.8× 86 0.7× 104 1.4× 50 450
Mingzhi Zhang China 9 334 0.9× 110 0.8× 165 1.2× 78 0.7× 28 0.4× 19 432
Elizabeth Halton United States 14 555 1.5× 117 0.8× 129 1.0× 187 1.6× 30 0.4× 29 604
Lisa Marie Serrano United States 8 459 1.2× 116 0.8× 268 2.0× 169 1.4× 63 0.9× 9 543
Katherine D. Cummins United States 8 408 1.1× 281 2.0× 123 0.9× 147 1.3× 175 2.4× 18 595
Elizabeth Veloso United States 5 281 0.7× 97 0.7× 215 1.6× 89 0.8× 103 1.4× 13 420
Yaohui Wu China 9 263 0.7× 120 0.8× 63 0.5× 80 0.7× 94 1.3× 26 379
Liora M. Schultz United States 10 347 0.9× 132 0.9× 202 1.5× 77 0.7× 50 0.7× 41 455
Xue Lin United States 6 441 1.2× 160 1.1× 138 1.0× 120 1.0× 25 0.3× 10 516
Pınar Ataca Atilla United States 8 267 0.7× 121 0.9× 115 0.9× 102 0.9× 48 0.7× 20 346

Countries citing papers authored by Yvette Bernal

Since Specialization
Citations

This map shows the geographic impact of Yvette Bernal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvette Bernal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvette Bernal more than expected).

Fields of papers citing papers by Yvette Bernal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvette Bernal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvette Bernal. The network helps show where Yvette Bernal may publish in the future.

Co-authorship network of co-authors of Yvette Bernal

This figure shows the co-authorship network connecting the top 25 collaborators of Yvette Bernal. A scholar is included among the top collaborators of Yvette Bernal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvette Bernal. Yvette Bernal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shah, Gunjan L., Tomalika R. Ullah, MM Hafeez, et al.. (2025). Infusional N-Acetylcysteine Enhances CAR T Cell Persistence in Patients with Aggressive B-Cell Lymphomas. Transplantation and Cellular Therapy. 31(2). S238–S239.
2.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2021). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 35(11). 3268–3271. 26 indexed citations
3.
Geyer, Mark B., Isabelle Rivière, Brigitte Sénéchal, et al.. (2019). Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. JCI Insight. 4(9). 69 indexed citations
4.
Perica, Karlo, Jessica Flynn, Kevin J. Curran, et al.. (2019). Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL.. Journal of Clinical Oncology. 37(15_suppl). 2520–2520. 9 indexed citations
5.
6.
Park, Jae H., Maria Lia Palomba, Connie Lee Batlevi, et al.. (2018). A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation. Blood. 132(Supplement 1). 224–224. 37 indexed citations
7.
Maslak, P., Tao Dao, Yvette Bernal, et al.. (2018). Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Advances. 2(3). 224–234. 121 indexed citations
8.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2017). Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy.. Journal of Clinical Oncology. 35(15_suppl). 7008–7008. 13 indexed citations
9.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2017). A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia.. Journal of Clinical Oncology. 35(15_suppl). TPS7568–TPS7568. 6 indexed citations
10.
Sauter, Craig S., Isabelle Rivière, Brigitte Sénéchal, et al.. (2017). A PHASE I TRIAL OF 19‐28Z CAR‐T CELLS POST‐HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT‐ASCT) FOR RELAPSED AND REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). Hematological Oncology. 35(S2). 138–139. 2 indexed citations
11.
Maslak, P., Tao Dao, Yvette Bernal, et al.. (2016). Phase II trial of WT1 analog peptide vaccine in adults with acute myeloid leukemia (AML) in first complete remission (CR).. Journal of Clinical Oncology. 34(15_suppl). 7005–7005. 3 indexed citations
12.
Park, Jae H., Isabelle Rivière, Xiuyan Wang, et al.. (2015). 475. Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL. Molecular Therapy. 23. S188–S189. 1 indexed citations
13.
Park, Jae Hong, Isabelle Rivière, Xiuyan Wang, et al.. (2015). Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL.. Journal of Clinical Oncology. 33(15_suppl). 7010–7010. 32 indexed citations
14.
15.
16.
17.
18.
Park, Jae H., Isabelle Rivière, Xiuyan Wang, et al.. (2013). Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL. Blood. 122(21). 874–874. 7 indexed citations
19.
Davila, Marco L., Isabelle Rivière, Xiuyan Wang, et al.. (2013). Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy. Blood. 122(21). 69–69. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunrong Tong Breakdown of academic impact, for papers by Mingzhi Zhang Breakdown of academic impact, for papers by Elizabeth Halton Breakdown of academic impact, for papers by Lisa Marie Serrano Breakdown of academic impact, for papers by Katherine D. Cummins Breakdown of academic impact, for papers by Elizabeth Veloso Breakdown of academic impact, for papers by Yaohui Wu Breakdown of academic impact, for papers by Liora M. Schultz Breakdown of academic impact, for papers by Xue Lin Breakdown of academic impact, for papers by Pınar Ataca Atilla
Rankless by CCL
2026